FIG 3.

Comparison of the muropeptide composition and abundance of soluble PGN substrates following treatment with EcLdcA and ApLdcA. (A) Mutanolysin-derived E. coli muropeptides were treated with EcLdcA and ApLdcA and subjected to the same LC-MS/MS analysis used for the data in Fig. 2. (B) Areas were baseline subtracted and normalized by sample. For each compound, the data shown are the average percentages of total PGN from three replicates (see Table S1). Comparisons between treatments were made using Tukey’s HSD test with adjustment for false discovery. All bars shown represent P values of <0.05.